> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Antivert Not Withdrawn Due to Safety/Efficacy: FDA
- URL: https://www.fdaweb.com/antivert-not-withdrawn-due-to-safety-efficacy-fda/
- Published: 2019-04-08T12:00:00.000Z
- Updated: 2026-09-15T01:18:55.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5143811

*Federal Register* notice: FDA has determined that Casper Pharma’s Antivert (meclizine hydrochloride) chewable tablets were not withdrawn from sale for reasons of safety or effectiveness. Antivert is indicated for treating vertigo associated with diseases affecting the vestibular system. The determination allows FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2019-04-05/pdf/2019-06656.pdf?ref=fdaweb.com).